<div id="readability-page-1"><p>Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has been assigned an average recommendation of &#34;Hold&#34; from the nine research firms that are currently  covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one  has given a hold recommendation and four have issued  a buy recommendation on  the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.25.</p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>Several equities research analysts recently issued reports on the stock. JPMorgan Chase &amp; Co. dropped their target price on shares of Novavax from $7.00 to $6.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 18th. TD Cowen dropped their price target on Novavax from $8.00 to $7.00 and set a &#34;hold&#34; rating on the stock in a research note on Tuesday, November 4th. B. Riley Financial  reaffirmed a &#34;buy&#34; rating and issued a $16.00 price objective (down previously from $18.00) on shares of Novavax in a report on Monday, November 10th. BTIG Research  reissued a &#34;buy&#34; rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, January 20th. Finally, Wall Street Zen cut Novavax from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, January 31st.</p><p><b>View Our Latest Research Report on NVAX</b></p><h2>Institutional Trading of Novavax</h2><ul><li>Is Biotech’s Bull Run Over? Examining Election Impacts</li></ul><p>Several large investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in  Novavax during the third quarter valued at approximately $33,000.  Flagship Harbor Advisors LLC bought a new stake in shares of  Novavax during the 4th quarter valued at $33,000.  Danske Bank A S purchased a new stake in shares of  Novavax in the 3rd quarter worth $64,000.  Mirae Asset Global Investments Co. Ltd. increased its stake in shares of  Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,617 shares in the last quarter.  Finally, State of Wyoming bought a new position in  Novavax in the 2nd quarter worth $52,000. 53.04% of the stock is currently owned by institutional investors. </p><h2>Novavax Price Performance</h2><p>Shares of Novavax stock opened at $9.20 on Friday. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93. The firm has a market capitalization of $1.50 billion, a PE ratio of 5.14 and a beta of 2.58. The business's 50-day moving average price is $8.01 and its 200-day moving average price is $7.97. Novavax has a 12 month low of $5.01 and a 12 month high of $10.64. </p><h2>Novavax Company Profile</h2> (Get Free Report)<ul><li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li></ul><p>Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.  </p><p>The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Novavax</li><li>Elon Musk already made me a “wealthy man”</li><li>America’s 1776 happening again</li><li>[How To] Invest Pre-IPO In SpaceX With $100!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Elon Musk: This Could Turn $100 into $100,000</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlZBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novavax Right Now?</h2><p>Before you consider Novavax, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.</p><p>While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

NVAX

<p>Novavax, Inc. (NASDAQ:NVAX) has received a consensus rating of "Hold" from nine research firms. The recommendations include four sell, one hold, and four buy ratings. The average price target is $11.25. Recent target price adjustments include JPMorgan lowering it to $6.00 and TD Cowen to $7.00, while B. Riley maintains a buy rating with a target of $16.00. Institutional investors hold 53.04% of the stock, which opened at $9.20, with a market cap of $1.50 billion and a PE ratio of 5.14.</p>

Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of "Hold" from Brokerages